ターナー症候群の世界市場：2024～2031年

概要

世界のターナー症候群市場は、2023年に41億2,640万米ドルに達し、2031年には66億5,168万米ドルに達すると予測され、予測期間2024-2031年にはCAGR 6.1％で成長すると予測されます。

ターナー症候群は、X染色体が1本欠損している病態であり、その結果、発達にいくつか問題が生じます。こ疾患は女性にみ見られ、原因は不明であり、ランダムな事象に起因すると考えられています。ターナー症候群患者に見られる最も一般的な症状は、低身長、卵巣未発達、一部患者では学習障害です。ターナー症候群患者では、先天性心疾患、腎臓異常、甲状腺機能低下症リスクが高くなっています。

ターナー症候群治療は、主に症状緩和に重点を置いています。最も一般的な治療は、成長ホルモン療法と性ホルモン補充療法であり、常に健康診断を受け、心理療法を受けることです。ターナー症候群女性大部分は妊娠しない可能性があるため、不妊治療は治療選択肢一つであるが、リスクも伴います。

市場力学

促進要因

研究開発の活発化

ターナー症候群の主な症状は、低身長と卵巣の未発達です。これらの症状を治療するための主な治療選択肢は、成長ホルモンの補充と性ホルモン補充療法です。成長ホルモンと性ホルモン補充療法は、多くの症状に対して規制当局から長い間承認されています。より良い製品を市場に送り出すために、いくつかの企業が投資を行っています。これらの製品は、ターナー症候群の症状の治療も目的としています。

例えば、2023年6月、米国FDAはファイザー社のNGENLA（somatrogon）を承認しました。NGENLAは週1回投与のヒト成長ホルモンアナログ製剤で、内因性成長ホルモンの分泌不全により成長不全に陥っている3歳以上の小児患者の治療に適応があります。このホルモンはターナー症候群および成長ホルモン分泌不全症（GHD）の治療に使用できます。

2023年5月、ノボノルディスクは、欧州医薬品庁（EMA）のヒト用医薬品委員会（CHMP）が、成長ホルモン分泌不全症およびターナー症候群による成長不全を有する3歳以上の小児および青年期における内因性成長ホルモンの補充として、週1回投与のソグロヤ（一般名：ソマパシタン）を推奨する肯定的見解を示したと発表しました。

さらに、生物学的製剤である長時間作用型成長ホルモン製剤ロナペグソマトロピンのターナー症候群の思春期前児を対象とした第2相臨床試験が2023年2月に開始されました。この試験はAscendis Pharma A/Sがスポンサーとなり、2026年6月までの終了を目指しています。

2024年3月、ターナー症候群患者を対象としたボソリチドの第2相試験が開始されました。ボソリチドはC型ナトリウム利尿ペプチド（CNP）アナログで、成長板内の軟骨細胞を標的として細胞増殖と肥大を促進します。ターナー症候群と低身長の患者は、ボソリチド治療に反応し、成長速度が増大するという仮説があります。

さらに、認知度の向上と診断率の上昇、有病率の増加は、市場成長をさらに押し上げると予想される主な要因です。

抑制要因

治療費の高さは、予測期間における市場成長の抑制要因となり得えます。ターナー症候群の患者は長期的な治療を受けなければならないが、成長ホルモンやエストロゲンは主要な選択肢であり、患者集団によっては高額になる可能性があります。

目次

第1章 調査手法と調査範囲

第2章 定義と概要

第3章 エグゼクティブサマリー

第4章 市場力学

• 影響要因
  • 促進要因
    • 研究開発活動の活発化
    • ターナー症候群の有病率の上昇
  • 抑制要因
    • 治療費の高騰
  • 機会
  • 影響分析

第5章 産業分析

• ポーターのファイブフォース分析
• サプライチェーン分析
• 価格分析
• 規制分析
• アンメットニーズ
• PESTEL分析
• 特許分析
• SWOT分析

第6章 薬剤クラス別

• モノソミーターナー症候群
• モザイクターナー症候群

第7章 治療タイプ別

• ホルモン補充療法
  • 成長ホルモン療法
  • エストロゲン補充療法（ERT）
  • 甲状腺補充療法
• 補助療法

第8章 エンドユーザー別

• 病院
• 専門クリニック
• 在宅医療
• その他

第9章 地域別

• 北米
  • 米国
  • カナダ
  • メキシコ
• 欧州
  • ドイツ
  • 英国
  • フランス
  • イタリア
  • スペイン
  • その他欧州
• 南米
  • ブラジル
  • アルゼンチン
  • その他南米
• アジア太平洋
  • 中国
  • インド
  • 日本
  • 韓国
  • その他アジア太平洋地域
• 中東・アフリカ

第10章 競合情勢

• 競合シナリオ
• 市況/シェア分析
• M&A分析

第11章 企業プロファイル

• Pfizer Inc.
  • 会社概要
  • 製品ポートフォリオと説明
  • 財務概要
  • 主な発展
• Novo Nordisk A/S
• Eli Lilly and Company
• Merck KGaA
• Ferring B.V.
• F. Hoffmann-La Roche Ltd
• Sandoz Inc.
• Ascendis Pharma
• AnkeBio Co., Ltd
• Changchun GeneScience Pharmaceutical Co., Ltd.

第12章 付録

Overview

The global Turner syndrome market reached US$ 4,126.40 million in 2023 and is expected to reach US$ 6,651.68 million by 2031, growing at a CAGR of 6.1% during the forecast period 2024-2031.

Turner syndrome is a condition in which one X chromosome is missing, which results in several developmental problems. This condition is only seen in females and the reason is unknown and is believed to result from a random event. The most common symptoms seen in a Turner syndrome patient are short stature, under-developed ovaries, and learning disabilities in some patients. The risk of congenital heart defects, kidney abnormalities, and hypothyroidism is higher in Turner syndrome patients.

The treatment of Turner syndrome majorly focuses on symptomatic relief. The most common treatments are growth hormone therapy, and sex hormone replacement therapy along with constant health checkups and psychological therapy. Majority of women with Turner syndrome may not conceive, hence fertility treatment is one of the therapeutic options, but it is also associated with risks.

Market Dynamics

Drivers

Rising research and development activities

The major symptoms of Turner syndrome are short stature and underdevelopment of ovaries. To treat these symptoms, the major therapeutic options are growth hormone supplementation, and sex hormone replacement therapy. The growth hormones and sex hormone replacement therapy have long been approved by regulatory bodies for many conditions. Several companies have been investing to bring better products into the market. These products are also aimed to treat symptoms of Turner syndrome.

For instance, in June 2023, the U.S. FDA approved Pfizer's NGENLA (somatrogon), a once-weekly human growth hormone analog indicated for the treatment of pediatric patients aged three years and older who have growth failure due to inadequate secretion of endogenous growth hormone. This hormone can be used in the treatment of Turner syndrome and growth hormone deficiency disease (GHD).

In May 2023, Novo Nordisk announced that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has given a positive opinion by recommending once-weekly Sogroya (somapacitan) for the replacement of endogenous growth hormone in children aged three years and above, and adolescents with growth failure due to growth hormone deficiency and Turner syndrome.

Moreover, a phase 2 clinical trial was initiated in February 2023, for a biologic drug Lonapegsomatropin, a long-acting growth hormone product in prepubertal individuals with Turner syndrome. The trial is sponsored by Ascendis Pharma A/S and aims to finish by June 2026.

In March 2024, a phase 2 trial was initiated for the drug Vosoritide for Turner syndrome patients. Vosoritide is a C-type natriuretic peptide (CNP) analog, that targets chondrocytes within the growth plate leading to increased cell proliferation and hypertrophy. It is hypothesized that patients with Turner syndrome and short stature will respond to vosoritide treatment leading to increased growth velocity.

Moreover, the rising awareness and increasing diagnosis rate, growing prevalence are the major factors that are expected to further boost the market growth.

Restraints

The high cost of treatment can be a restraining factor for the market growth in the forecast period. The patient with Turner syndrome must take long-term treatment, the growth hormones and the estrogens which are mainstay options, can be expensive for some patient populations.

For more details on this report - Request for Sample

Segment Analysis

The global Turner Syndrome market is segmented based on disorder type, treatment type, end-users, and region.

The hormone replacement therapy in the treatment type segment accounted for major share for the global Turner syndrome market

The administration of ERT and GH is the main treatment for Turner syndrome. Despite being distinct therapeutic approaches, GHT and ERT frequently complement one another to maximize the development potential and general health of people with Turner syndrome. The first goal of GHT is for girls to reach a height that will not place physical limits on them and to begin sexual maturation at a similar age to their peers. When a person reaches adolescence and growth hormone therapy has produced adequate linear development, estrogen therapy is typically started. At this point, the administration of estrogen aids in the development of secondary sexual traits and the accomplishment of typical pubertal developmental milestones.

According to the National Health Service (NHS), growth hormone therapy is a daily injection, starting at around 5 or 6 years of age or later. It's usually continued until 15 or 16, helping the girl gain on average around 5cm (about 2in) in height. The treatment span would be close to 10 years. Whereas hormone replacement therapy is given to Turner syndrome patients until they attain menopause. Oestrogen replacement therapy is usually started around the time of normal puberty which is around 11 years of age. This is usually continued till they attain 50 years of age.

Hence, hormone therapy plays a crucial role in patients with Turner syndrome and is expected to have the highest market share in the treatment type segment.

Geographical Analysis

North America is expected to dominate the market with a 47.6% share in the global Turner syndrome market.

North America is well known for its advancements in the healthcare industry. The major countries in the region such as the U.S. and Canada are well known for their investments in healthcare. The favorable yet stringent regulatory policies, favorable environment for research and development activities, higher demand for advanced therapeutics, and high investments in the industry are the factors that are contributing to the region's dominance.

Moreover, the region has the highest prevalence of Turner syndrome. For instance, according to the National Organization for Rare Disorders, Turner syndrome affects approximately 1 in 2,000-2,500 live female births, and nearly 70,000 females in the United States have Turner syndrome. Due to the availability of advanced healthcare systems, well well-trained physicians, the diagnosis rate is this condition is high, and patients in the region get timely diagnosis and treatment with advanced therapeutical modalities.

Market Segmentation

By Disorder Type

• Monosomy Turner Syndrome
• Mosaic Turner Syndrome

By Treatment Type

• Hormone Replacement Therapy
  • Growth Hormone Therapy
  • Estrogen Replacement Therapy (ERT)
  • Thyroid Replacement Therapy
• Supplemental Therapy

By End-Users

• Hospitals
• Specialty Clinics
• Homecare
• Others

By Region

• North America
  • U.S.
  • Canada
  • Mexico
• Europe
  • Germany
  • U.K.
  • France
  • Spain
  • Italy
  • Rest of Europe
• South America
  • Brazil
  • Argentina
  • Rest of South America
• Asia-Pacific
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Middle East and Africa

Competitive Landscape

The major players in the Turner Syndrome market include Pfizer Inc., Novo Nordisk A/S, Eli Lilly and Company, Merck KGaA, Ferring B.V., F. Hoffmann-La Roche Ltd, Sandoz Inc., Ascendis Pharma, AnkeBio Co., Ltd, and Changchun GeneScience Pharmaceutical Co., Ltd. among others.

Why Purchase the Report?

• To visualize the global TTurner Syndrome market segmentation based on disorder type, treatment type, end-users and region as well as understand key commercial assets and players.
• Identify commercial opportunities by analyzing trends and co-development
• Excel data sheet with numerous data points of Turner Syndrome market-level with all segments.
• PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
• Product mapping available as excel consisting of key products of all the major players.

The global Turner Syndrome market report would provide approximately 62 tables, 51 figures, and 187 Pages.

Target Audience 2024

• Manufacturers/ Buyers
• Industry Investors/Investment Bankers
• Research Professionals
• Emerging Companies

Table of Contents

1. Methodology and Scope

• 1.1. Research Methodology
• 1.2. Research Objective and Scope of the Report

2. Definition and Overview

3. Executive Summary

• 3.1. Snippet by Disorder Type
• 3.2. Snippet by Treatment Type
• 3.3. Snippet by End-Users

4. Dynamics

• 4.1. Impacting Factors
  • 4.1.1. Drivers
    • 4.1.1.1. Rising research and development activities
    • 4.1.1.2. Rising prevalence of Turner syndrome
  • 4.1.2. Restraints
    • 4.1.2.1. High cost of treatment
  • 4.1.3. Opportunity
  • 4.1.4. Impact Analysis

5. Industry Analysis

• 5.1. Porter's Five Force Analysis
• 5.2. Supply Chain Analysis
• 5.3. Pricing Analysis
• 5.4. Regulatory Analysis
• 5.5. Unmet Needs
• 5.6. PESTEL Analysis
• 5.7. Patent Analysis
• 5.8. SWOT Analysis

6. By Drug Class

• 6.1. Introduction
  • 6.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disorder Type
  • 6.1.2. Market Attractiveness Index, By Disorder Type
• 6.2. Monosomy Turner Syndrome*
  • 6.2.1. Introduction
  • 6.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
• 6.3. Mosaic Turner Syndrome

7. By Treatment Type

• 7.1. Introduction
  • 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
  • 7.1.2. Market Attractiveness Index, By Treatment Type
• 7.2. Hormone Replacement Therapy*
  • 7.2.1. Introduction
  • 7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 7.2.3. Growth Hormone Therapy
  • 7.2.4. Estrogen Replacement Therapy (ERT)
  • 7.2.5. Thyroid Replacement Therapy
• 7.3. Supplemental Therapy

8. By End-Users

• 8.1. Introduction
  • 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-Users
  • 8.1.2. Market Attractiveness Index, By End-Users
• 8.2. Hospitals*
  • 8.2.1. Introduction
  • 8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
• 8.3. Specialty Clinics
• 8.4. Homecare
• 8.5. Others

9. By Region

• 9.1. Introduction
  • 9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
  • 9.1.2. Market Attractiveness Index, By Region
• 9.2. North America
  • 9.2.1. Introduction
  • 9.2.2. Key Region-Specific Dynamics
  • 9.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disorder Type
  • 9.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
  • 9.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-Users
  • 9.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 9.2.6.1. The U.S.
    • 9.2.6.2. Canada
    • 9.2.6.3. Mexico
• 9.3. Europe
  • 9.3.1. Introduction
  • 9.3.2. Key Region-Specific Dynamics
  • 9.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disorder Type
  • 9.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
  • 9.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-Users
    • 9.3.5.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 9.3.5.2. Germany
    • 9.3.5.3. UK
    • 9.3.5.4. France
    • 9.3.5.5. Italy
    • 9.3.5.6. Spain
    • 9.3.5.7. Rest of Europe
• 9.4. South America
  • 9.4.1. Introduction
  • 9.4.2. Key Region-Specific Dynamics
  • 9.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disorder Type
  • 9.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
  • 9.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-Users
    • 9.4.5.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 9.4.5.2. Brazil
    • 9.4.5.3. Argentina
    • 9.4.5.4. Rest of South America
• 9.5. Asia-Pacific
  • 9.5.1. Introduction
  • 9.5.2. Key Region-Specific Dynamics
  • 9.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disorder Type
  • 9.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
  • 9.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-Users
    • 9.5.5.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 9.5.5.2. China
    • 9.5.5.3. India
    • 9.5.5.4. Japan
    • 9.5.5.5. South Korea
    • 9.5.5.6. Rest of Asia-Pacific
• 9.6. Middle East and Africa
  • 9.6.1. Introduction
  • 9.6.2. Key Region-Specific Dynamics
  • 9.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disorder Type
  • 9.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
  • 9.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-Users

10. Competitive Landscape

• 10.1. Competitive Scenario
• 10.2. Market Positioning/Share Analysis
• 10.3. Mergers and Acquisitions Analysis

11. Company Profiles

• 11.1. Pfizer Inc.*
  • 11.1.1. Company Overview
  • 11.1.2. Product Portfolio and Description
  • 11.1.3. Financial Overview
  • 11.1.4. Key Developments
• 11.2. Novo Nordisk A/S
• 11.3. Eli Lilly and Company
• 11.4. Merck KGaA
• 11.5. Ferring B.V.
• 11.6. F. Hoffmann-La Roche Ltd
• 11.7. Sandoz Inc.
• 11.8. Ascendis Pharma
• 11.9. AnkeBio Co., Ltd
• 11.10. Changchun GeneScience Pharmaceutical Co., Ltd.

LIST NOT EXHAUSTIVE

12. Appendix

• 12.1. About Us and Services
• 12.2. Contact Us